Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a common public health problem, affecting pregnant women. However, the impacts of MDR-TB and its medication on pregnancy and perinatal outcomes has been poorly understood and inconsistently reported. Therefore, using the available literature, we aim to determine whether MDR-TB and MDR-TB medications during pregnancy impact maternal and perinatal outcomes.
. It has been estimated that more than 200 000 pregnant women are affected by TB globally; with 41% and 31% of the cases occurred in African and South-East Asian countries, respectively (2) . The emergence of multidrug-resistant tuberculosis (MDR-TB) with resistance to rifampicin and isoniazid (the two most important firstline therapeutic agents) and extensively resistant TB (XDR-TB), with additional resistance to a fluoroquinolone and a second-line injectable drug, has become a major global concern that poses additional challenges for the treatment of TB among pregant women (3) . In 2017, globally, there were an estimated 490 000 incident MDR-TB cases, of which 9% were XDR-TB cases (4) .
MDR-TB is common among pregnant women and may result in a higher risk of pregnancy-related complications and perinatal death (1, 5) . It has also been suggested that MDR-TB during pregnancy could potentially trigger an increased risk of adverse birth outcomes such as spontaneous abortion, small for gestational age, and low birth weight (6) (7) (8) . The impact of MDR-TB in pregnant women can be aggravated by several factors such as the severity of the disease, the site of infection and the treatment regimen, and substantially varies from mild symptoms to severe compilations and sometimes death (5, 9) . Pregnant women with untreated MDR-TB are at increased risks of maternal and infant mortality, suggesting treatment with second-line TB drugs (10) . However, as the treatment of MDR-TB takes longer duration and is more toxic than DS-TB, the risk of adverse birth outcomes such as miscarriage, stillbirth, preterm birth, low birth-weight (LBW) is suggested to be higher in patients with MDR-TB than in patients with DS-TB (11) . These adverse birth outcomes often occur as a result of the disease process itself or due to side effects related to second-line TB medications such as fluoroquinolones, aminoglycosides, ethionamide, and prothionamide. Some of these drugs have been identified to have teratogenic effects. For example, aminoglycosides including streptomycin, kanamycin, and amikacin have been shown to impact fetal birthweight and hearing capacity (6, 12, 13) . As a result, some studies have recommended termination of pregnancy (8, 14) and others have suggested reducing the dose of teratogenic drugs or suspending the treatment during pregnancy (15, 16) . On the contrary, some studies did not find an association between MDR-TB medications and the perinatal outcomes (17) .
However, previous studies have provided such conflicting evidence based on individual studies with a small sample size (8, 18, 19) , and adequate data regarding the impact of second-line MDR-TB drugs in pregnant women are lacking (14) .
As most previous studies revealed inconsistent results, mainly because of limited statistical power, a comprehensive systematic review including meta-analysis is required to have clarity regarding the impact of MDR-TB and second-line TB drugs on perinatal outcomes. Quantification of the effects of MDR-TB and its medication on birth outcomes is essential to inform service providers and policymakers in allocating resources and in the prevention of adverse birth outcomes in countries where MDR-TB is prevalent.
The objective of the study
The aim of this systematic review and meta-analysis is to assess the impact of MDR-TB and MDR-TB medications during pregnancy on adverse maternal and birth outcomes.
Methods

Search strategy
This systematic review and meta-analysis will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (20) . Systematic searching will be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 5 conducted in PubMed, Scopus, and Web of Science databases to identify all potential studies that reported adverse maternal and perinatal outcomes among pregnant women who had MDR-TB diagnosis or exposure to MDR-TB medications during pregnancy. The search will be conducted from inception of each database to November 2019, with an English language restriction. The
Medical Subject Headings (MeSH) term and combination of keywords related to pregnancy, MDR-TB and MDR-TB medications, and pregnancy outcomes will be used for the search. A complete searching strategy for the PubMed database is available in the supplementary file (Table S1 ). The reference lists and citations of the retrieved articles will be checked manually for additional studies. The authors of the papers will be contacted through email when there is a need for additional information.
Eligibility criteria
Inclusion criteria: Studies will be included in the systematic review if they evaluate any maternal morbidity and mortality as well as perinatal adverse outcomes among pregnant women with MDR-TB (with or without MDR-TB medications). The selection criteria to identify potential studies will be study population (pregnant women), intervention (MDR-TB and/or its medication during pregnancy), comparator (pregnancies with no MDR-TB, pregnancies with MDR-TB not receiving treatment), and outcomes (adverse perinatal outcomes, and maternal morbidity and mortality).
MDR-TB medications will be defined, according to the recent WHO guideline on drug-resistant tuberculosis treatment, as second-line TB agents that are recommended for the treatment of drugresistant TB (21) .
Exclusion criteria: we will exclude correspondence, reviews, editorials, and conference abstracts.
Studies conducted only on drug-susceptible TB or on animals will be also excluded. When multiple studies used the same data, we will include the study with the most detailed clinical data, with the largest sample size or with the longest follow-up period to avoid duplication.
Outcomes of the study
The review includes both perinatal adverse outcomes, and the maternal morbidity and mortality. Table 1 shows the definition of the perinatal adverse outcomes and the maternal morbidity and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 mortality outcomes of the study. The outcomes of the study will be recorded as prevalence, incidence, relative risks or odds ratios, as reported in the individual papers. 
Data extraction
All identified articles from the systematic searching will be uploaded into Rayyan (https://rayyan.qcri.org). Two researchers (KAA and AJ) will independently screen the titles and abstracts of the studies and will then review the full text based on the eligibility criteria. The two researchers will compare the results and disagreements will be resolved through discussion. If consensus is not reached between these two researchers, disagreements will be resolved by discussion with a third investigator (AAA).
Data from the included studies will be extracted and compiled using a standardised excel spreadsheet. We will extract information from each study on the last name of first author, year of data collection and publication, report type (grey literature v published studies), study country, study design, and data source. Information will be also collected on maternal age, sample size, effect size as reported by a study, multiple pregnancies, type of pregnancy outcomes, and number of cases with adverse birth outcomes. When available, the following additional information will 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7   be also extracted from the primary studies: percentage of resistance to particular TB medicines,   duration of MDR-TB treatment in months, percentage of pregnant women with HIV infection, and percentage of pregnant women with diabetes mellitus. Moreover, we will make an effort to include relevant information unavailable to the original study such as socio-economic setting (e.g., poor or rich country, income level for each country, WB member or not), geographical dimension (the state/province where the study is conducted). A data extraction sheet is available in the supplementary information (Table S2 ).
Quality and bias assessment
The methodological quality of the included studies will be assessed independently by the same two investigators (KAA and AJ), using a modified version of the Newcastle-Ottawa Quality Assessment Scales (22) . This tool has scores ranging from zero to nine; scores between one and four will be defined as low quality, scores between five and seven will be defined as medium quality, and scores between eight and nine will be defined as high quality. Publication bias will be assessed graphically by a funnel plot and statistically using a recently developed Robust Variance Estimation (RVE) technique (23, 24) .
Data analysis
A systematic narrative synthesis will be conducted to describe the outcomes of the study. When two or more studies are available, a random-effects meta-analysis will be used to obtain a pooled estimate value for each of the outcomes of interest. Heterogeneity between studies will be examined using the Cochran's Q test and quantitatively measured by the index of heterogeneity squared (I 2 ) statistics and its 95% confidence interval (CI) (25) . Heterogeneity will be considered low, moderate and high when I 2 values are below 25%, between 25% and 75%, and above 75%, respectively (25) . When there is evidence of significant heterogeneity, the sources of this will be explored through meta-regression using study characteristics as covariates. The Hedges et al.
(2010) (26) and the Tipton (2015) small-sample corrected RVE method (27) will be applied to perform the meta-regression, this approach handles non-independent effect sizes without knowledge of the within-study covariance structure. Unlike the traditional meta-regression approaches, the RVE method has some unique benefits such as: a) the coefficients are consistent estimates of the underlying population parameters under a broad set of conditions including nonnormality; b) the results do not need the predictor variables to be fixed; c) RVE yields valid (26) show that the RVE approach performs well when the number of studies is large.
However, Tipton (2015) (27) made small-sample adjustments to both the RVE estimator and degrees of freedom and it has been suggested that the RVE method can also perform well when the number of studies is small, as few as ten. An inverse variance weighting will be used to provide asymptotically accurate estimates of standard errors and valid inferences. This approach is distribution-free, provides valid point estimates, standard errors and performs an appropriate hypothesis test even when the degree and structure of dependence between effect sizes are unknown, hence, the statistical inferences made will be unbiased and correct.
Patient and public involvement
No patient will be involved in the study.
Discussion and conclusion
This comprehensive systematic review will quantify the impacts of MDR-TB and second-line TB medication on adverse maternal and birth outcomes such as prematurity, low birth weight, and small for gestational age, and various other obstetrical and perinatal outcomes. The results will provide compressive information essential for healthcare providers and policymakers to better understand the impact of MDR-TB and its medication on adverse maternal and birth outcomes and to design appropriate treatment regimen and follow up for pregnant women with MDR-TB. This review also identifies research gaps in the literature regarding the subject and provides a basis for future studies. This review does not require a formal ethics approval as publicly available published studies will be used. The findings of this review will be disseminated through publication in a peer-reviewed journal and presentation at relevant national and international conferences and scientific meetings. The reviewer will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Contributors: KAA, AAA, and AJ conceived of the study, developed the search strategy, and drafted the protocol. All authors critically revised the manuscript for methodological and intellectual content and have read and approved the final manuscript. [Mesh] or "mdr-tb" or "xdr-tb" or "secondline tuberculosis drugs" or "fluoroquinolones" or "aminoglycosides" or "levofloxacin" or "moxifloxacin" or "bedaquiline" or "linezolid" or "clofazimine" or "cycloserine" or "terizidone" or "delamanid" or "imipenemcilastatin" or "meropenem" or "amikacin" or "ethionamide" or "prothionamide" or "p-aminosalicylic acid" 3 outcomes "adverse birth outcomes" OR abortion OR miscarriage OR termination OR stillbirth OR premature OR preterm OR birthweight OR "birth weight" OR "gestational age" OR death OR morbidity OR "pregnancy complications" OR "birth complications" 4 Search #1 AND #2 AND #3 
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Study records: Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 6&7 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 6
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41 Ethics and dissemination: As it will be a systematic review and meta-analysis based on 42 previously published evidence, there will be no requirement for ethical approval. Findings will be 43 published in the peer-reviewed journal and will be presented at various conferences.
44 Strengths and limitations of this study 46  As to our knowledge, this systematic review will be the first to synthesise and quantify 47 the impact of MDR-TB and its medication on adverse birth and maternal outcomes.
48
 Databases will be searched without time restrictions and independent evaluation will be 49 employed.
50
 A recently developed robust variance meta-analysis technique will be applied to detect 51 and correct for publication bias.
52
 The potential limitation of this review could be the heterogeneity of studies in outcomes 53 of interest.
54
 English language restriction is the other limitation.
55 Introduction 71 compilations and sometimes death (5, 9) . Pregnant women with untreated MDR-TB are at 72 increased risks of maternal and infant mortality, suggesting treatment with second-line TB drugs 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 125 Exclusion criteria: we will exclude correspondence, reviews, editorials, and conference abstracts.
126 Studies conducted only on drug-susceptible TB or on animals will be also excluded. When multiple 127 studies used the same data, we will include the study with the most detailed clinical data, with the 128 largest sample size or with the longest follow-up period to avoid duplication.
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Outcomes of the study 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The review includes both perinatal adverse outcomes, and the maternal morbidity and mortality. 131 We will include studies that reported outcomes of pregnancies complicated by MDR-TB and 132 non-drug resistant TB to construct risk ratios for each study and look for a pooled risk ratio.
133 Table 1 shows the definition of the perinatal adverse outcomes and the maternal morbidity and 134 mortality outcomes of the study. The outcomes of the study will be recorded as prevalence, 135 incidence, and relative risks or odds ratios, as reported in the individual papers.
136 
Data extraction
138 All identified articles from the systematic searching will be uploaded into Rayyan 139 (https://rayyan.qcri.org). Two researchers (KAA and AJ) will independently screen the titles and 140 abstracts of the studies and will then review the full text based on the eligibility criteria. The two 141 researchers will compare the results and disagreements will be resolved through discussion. If 142 consensus is not reached between these two researchers, disagreements will be resolved by 143 discussion with a third investigator (AAA).
144 Data from the included studies will be extracted and compiled using a standardised excel 145 spreadsheet. We will extract information from each study on the last name of the first author, year 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 147 study design, and data source. Information will be also collected on maternal age, sample size, 148 effect size as reported by a study, multiple pregnancies, type of pregnancy outcomes, and number 149 of cases with adverse birth outcomes. When available, the following additional information will 150 be also extracted from the primary studies: percentage of resistance to particular TB medicines, 151 duration of MDR-TB treatment in months, percentage of pregnant women with HIV infection, and 152 percentage of pregnant women with diabetes mellitus. Moreover, we will make an effort to include 153 relevant information unavailable to the original study such as socio-economic setting (e.g., poor 154 or rich country, the income level for each country, WB member or not), geographical dimension 155 (the state/province where the study is conducted). A data extraction sheet is available in the 156 supplementary information (Table S2) .
157
Quality and bias assessment 158 The methodological quality of the included studies will be assessed independently by the same 159 two investigators (KAA and AJ), using a modified version of the Newcastle-Ottawa Quality 160 Assessment Scales (22) . This tool has scores ranging from zero to nine; scores between one and 161 four will be defined as low quality, scores between five and seven will be defined as medium 162 quality, and scores between eight and nine will be defined as high quality. Publication bias will be 163 assessed graphically by a funnel plot and statistically using a recently developed Robust Variance 164 Estimation (RVE) technique (23, 24) .
165
Data analysis
166 A systematic narrative synthesis will be conducted to describe the outcomes of the study. When 167 two or more studies are available, a random-effects meta-analysis will be used to obtain a pooled 168 estimate value for each of the outcomes of interest. Heterogeneity between studies will be 169 examined using the Cochran's Q test and quantitatively measured by the index of heterogeneity 170 squared (I 2 ) statistics and its 95% confidence interval (CI) (25) . Heterogeneity will be considered 171 low, moderate and high when I 2 values are below 25%, between 25% and 75%, and above 75%, 172 respectively (25) . When there is evidence of significant heterogeneity, the sources of this will be 173 explored through meta-regression using study characteristics as covariates. The Hedges et al. (2015) small-sample corrected RVE method (27) will be applied to 175 perform the meta-regression, this approach handles non-independent effect sizes without (26) show that the RVE approach performs well when the number of studies is large. 183 However, Tipton (2015) (27) made small-sample adjustments to both the RVE estimator and 184 degrees of freedom and it has been suggested that the RVE method can also perform well when 185 the number of studies is small, as few as ten. An inverse variance weighting will be used to provide 186 asymptotically accurate estimates of standard errors and valid inferences. This approach is 187 distribution-free, provides valid point estimates, standard errors and performs an appropriate 188 hypothesis test even when the degree and structure of dependence between effect sizes are 189 unknown, hence, the statistical inferences made will be unbiased and correct. [Mesh] or "mdr-tb" or "xdr-tb" or "secondline tuberculosis drugs" or "fluoroquinolones" or "aminoglycosides" or "levofloxacin" or "moxifloxacin" or "bedaquiline" or "linezolid" or "clofazimine" or "cycloserine" or "terizidone" or "delamanid" or "imipenemcilastatin" or "meropenem" or "amikacin" or "ethionamide" or "prothionamide" or "p-aminosalicylic acid" 3 outcomes "adverse birth outcomes" OR abortion OR miscarriage OR termination OR stillbirth OR premature OR preterm OR birthweight OR "birth weight" OR "gestational age" OR death OR morbidity OR "pregnancy complications" OR "birth complications" 4 Search #1 AND #2 AND #3 Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
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42 Ethics and dissemination: As it will be a systematic review and meta-analysis based on 43 previously published evidence, there will be no requirement for ethical approval. Findings will be 44 published in the peer-reviewed journal and will be presented at various conferences. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Strengths and limitations of this study 47  As to our knowledge, this systematic review will be the first to synthesise and quantify 72 increased risks of maternal and infant mortality, suggesting treatment with second-line TB drugs 73 (10) . However, as the treatment of MDR-TB takes longer duration and is more toxic than DS-TB, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (6, 12, 13) . As a result, some studies have 81 recommended termination of pregnancy (8, 14) and others have suggested reducing the dose of 82 teratogenic drugs or suspending the treatment during pregnancy (15, 16) . On the contrary, some 83 studies did not find an association between MDR-TB medications and the perinatal outcomes (17) . 84 However, previous studies have provided such conflicting evidence based on individual studies 85 with a small sample size (8, 18, 19) , and adequate data regarding the impact of second-line MDR-86 TB drugs in pregnant women are lacking (14) . In addition, to the best of our knowledge, no MDR 87 trial currently conducted worldwide includes pregnant patients which presents a major obstacle to 88 develop guidance of what MDR-TB drugs are safe and effective in pregnancy.
89 As most previous studies revealed inconsistent results, mainly because of limited statistical power, 90 a comprehensive systematic review including meta-analysis is required to have clarity regarding 91 the impact of MDR-TB and second-line TB drugs on perinatal outcomes. Quantification of the 92 effects of MDR-TB and its medication on birth outcomes is essential to inform service providers 93 and policymakers in allocating resources and in the prevention of adverse birth outcomes in 94 countries where MDR-TB is prevalent.
95 The objective of the study 96 The aim of this systematic review and meta-analysis is to assess the impact of MDR-TB and 97 MDR-TB medications during pregnancy on adverse maternal and birth outcomes.
Methods
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Outcomes of the study
133 Table 1 shows the definition of the perinatal adverse outcomes and the maternal morbidity and 134 mortality outcomes of the study. The outcomes of the study will be recorded as prevalence, 135 incidence, relative risks or odds ratios, as reported in the individual papers.
Data extraction
144 Data from the included studies will be extracted and compiled using a standardised excel 145 spreadsheet. We will extract information from each study on the last name of the first author, year (Table S2) .
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Data analysis
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